Skip to main content
. Author manuscript; available in PMC: 2023 May 14.
Published in final edited form as: J Immunother. 2017 Jan;40(1):31–35. doi: 10.1097/CJI.0000000000000148

FIGURE 1.

FIGURE 1.

A, Overall survival of anti-programmed cell death-1 (PD-1) first versus BRAFi-first group. B, Survival of patients who received anti-PD-1 only, those who received BRAFi followed by anti-PD-1, and those who received anti-PD-1 followed by BRAFi.